
Sacituzumab Govitecan-hziy Plus Pembrolizumab Improves PFS in Patients With Metastatic Triple-Negative Breast Cancer
Sacituzumab govitecan-hziy (Trodelvy; Gilead Sciences) plus pembrolizumab (Keytruda; Merck & Co. Inc) met its primary end point in the ASCENT-04/KEYNOTE-D19 study (NCT05382286), demonstrating clinically meaningful improvements in progression-free …